ESMO 2017: Patient Advocacy Track

Bettina Ryll

The ESMO Patient Advocacy Track addresses research topics that directly impact cancer care, obviously in addition to medical research. Demands for participatory medicine as well as financial constraints are changing the way oncology is practised today and have brought forward new fields of research, so we have sessions on patient outcomes research (Sunday) as well as health service research (Friday).
Today's cancer patients are increasingly knowledgeable and connected. Patient advocacy groups are playing a major role in this and now increasingly leveraging the power of those patient networks for evidence-generation. The advocacy track is a good opportunity for anyone interested in this type of work to find out more!

Bettina Ryll, ESMO Patient Advocates Working Group Chair

Friday, 8 September 2017; Room: Palma

Welcome

Friday, 8 September, 14:00-14:30, Room Palma, Chairs: P. Casali (IT); B. Ryll (SE)

  • 14:00-14:15 Welcome by ESMO, P. Casali (IT)
  • 14:15-14:30 Welcome by the ESMO Patient Advocacy Working Group Chair, B. Ryll (SE)

Science by patients for patients

Friday, 8 September, 14:45-15:45, Room Palma, Chairs: B. Ryll (SE), TBC

  • 14:45-15:00 Science and advocacy: Why care about science? How to involve patients in research, J. Geissler (DE)
  • 15:00-15:15 Involvement of patients in pathology, Speaker TBC
  • 15:15-15:30 The citizen scientist – statistics for citizens, D.Dahly (IE)
  • 15:30-15:45 Discussion

Health services research in cancer

Friday, 8 September, 16:15-17:15, Room Palma, Chairs: Kathi Apostolidis (GR), TBC

  • 16:15-16:30 Health services research in Europe and its use for informing cancer policy, T. Albreht (SL)
  • 16:30-16:45 Cancer patient experience from referral to hospital performance, G. Lyratzopoulos (UK)
  • 16:45-17:00 What cancer patients want, Speaker TBC
  • 17:00-17:15 Discussion

As an applied field of research, health services research (HSR) is undertaken primarily to inform health care policy. However, the relationship between policy and HSR is not straightforward. Many policies are developed without taking account of available evidence. The objective is to provide an overview of the infrastructure and capacity of HSR in Europe, and to explore the links between HSR and policy in European countries.

Debate: Working with industry – inherent conflicts of interest?

Friday, 8 September, 17:30-19:00, Session details TBC

Saturday, 9 September 2017; Room: Palma

Immuno-oncology (Immunotherapy and its side effects)

Saturday, 9 September, 12:30-14:30 (Lunch 14:00-14:30), Room Palma, Chairs: Ana-Maria Forsea (RO), TBC

  • 12:30-12:50 Immuno-oncology: Overview of existing therapies and what is coming next? John Haanen (NL)
  • 12:50-13:10 Predicting response to immune therapies, Speaker TBC
  • 13:10-13:30 Interchangeability between immune therapies, Paolo Ascierto (IT)
  • 13:30-14:00 Discussion

Bio-ethical controversies and what they mean to research and European inequalities

Saturday, 9 September, 18:00-19:30, Room Palma, Chairs: Ananda Plate (BE), TBC

  • 18:00-18:15 The regulatory perspective, Speaker TBC
  • 18:15-18:30 The academic perspective, Speaker TBC
  • 18:30-18:45 The clinical researcher perspective, Speaker TBC
  • 18.45-19:00 The patient perspective (incl. fertility), Louise Bayne (UK)
  • 19:00-19:30 Discussion

Sunday, 10 September 2017; Room: Palma

Patient outcomes research

Sunday, 10 September, 12:00-14:30 (Lunch 14:00-14:30), Room Palma, Chairs: Ian Banks (UK), TBC

  • 12:30-12:45 How to integrate qualitative research into clinical trials, Annmarie Nelson (UK)
  • 12:45-13:00 What are meaningful patient outcomes and how to implement them, Speaker TBC
  • 13:00-13:15 Risk benefit assessment tool, Bettina Ryll (SE)
  • 13:15-13:30 Measuring Quality of Life and deltas of perceptions between HCPs and patients, Fabio Efficace (IT)
  • 13:30-14:00 Discussion

Rare cancers: More common than you think, more difficult to serve

Sunday, 10 September, 18:00-19:30, Room Palma, Chairs: Kathy Oliver (UK), Jean-Yves Blay (FR)

  • 18:00-18:15 he EURORDIS table: Similarities and differences of rare cancers and rare diseases, Kathy Oliver (UK)
  • 18:15-18:30 Joint actions on rare cancers, Paolo Casali (IT)
  • 18:30-18:45 What EUROCAN, the European Reference Network for Rare Cancers, will do for patients, Jean-Yves Blay (FR)
  • 18.45-19:00 The importance of adaptive pathways in rare cancers, Francesco Pignatti (UK)
  • 19:00-19:30 Discussion

Monday, 11 September 2017; Room: Palma

The Hans Keulen Memorial Debate

Monday, 10 September, 12:00-14:30 (Lunch 14:00-14:30), Room Palma, Chairs: Kathy Oliver (UK), TBC

  • Full session details will be annouced mid-April